CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

-Initiation of patient enrollment expected by year-end- -Initiation of patient enrollment expected by year-end- ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO , Nov. 16, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing